// App-Quantinova.ai

POS0190 (2022) : EFFICACY AND SAFETY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM TWO RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDIES

Researchers

Presenter

  • E. F. Morand

Principal Investigators

  • Y. Tanaka

  • R. Furie

  • E. Vital

  • R. van Vollenhoven

  • K. Kalunian

  • M. Mosca

  • T. Drner

  • D. J. Wallace

  • M. Silk

  • C. Dickson

  • I. De La Torre

  • G. Meszaros

  • B. Jia

  • B. Crowe

  • M. A. Petri

Medical Centers

  • Monash University, Centre for Inflammatory Diseases, Melbourne, Australia

  • University of Occupational and Environmental Health, Japan, The second department on internal medicine, Kitakyusyu, Japan

  • Northwell Health and Zucker School of Medicine, Division of Rheumatology, Northwell, United States of America

  • University of Leeds, Leeds Institue of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom

  • University Medical Centre, Clinical Immunology and Rheumatology, Amsterdam, Netherlands

  • University of California San Diego”, Division of Rheumatology, Allergy and Immunology, La Jolla, United States of America

  • University of Messina, Dept. of Clinical and Experimental Medicine, Messina, Italy

  • Charite University Medicine, Dept. Medicine/Rheumatology and Clinical Immunology, Berlin, Germany

  • Cedars-Sinai Medical Center/University California, Division of Rheumatology, Allergy and Immunology, Los Angeles, United States of America

  • Eli Lilly and Company, Indianapolis, United States of America

  • John Hopkins University School of Medicine, Division of Rheumatology, Baltimore, United States of America

Locations

  • Australia

  • Japan

  • United States

  • United Kingdom

  • Netherlands

  • Italy

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Lupus

Biomarkers

  • N/A

Drug/Treatment

  • Glucocorticoid

  • Baricitinib

  • BARI

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

  • Parallel Group

Phase

  • III

Study Id's

  • NCT02708095

  • NCT03616912

  • NCT03616964

Sponsors

  • Janssen Pharmaceutical

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved